Overexpression of NEK2 is observed in a number of cancers including breast cancer, pancreatic cancer, lung adenocarcinoma, cholangiocarcinoma, colorectal cancer (CRC) and non-Hodgkin lymphoma [12–18]. Here, NEK2 is linked to cholangiocarcinoma.